Effects of topical administration of a bisphosphonate (risedronate) on orthodontic tooth movements in rats.
In orthodontics, undesirable movement of anchor teeth during tooth movement and relapse of moved teeth after treatment are the main causes of unsuccessful results. If these tooth movements could be prevented with pharmacological agents, a less complex orthodontic force system and less extensive retention would be required. The purpose of this study was to examine the effect of topical administration of a bisphosphonate (risedronate), a potent blocker of bone resorption, on orthodontic tooth movements in rats. In the first experiment, both the right and left upper first molars were moved buccally with a standardized expansion spring under administration of risedronate. Risedronate solution was injected into the subperiosteum area adjacent to the left upper first molar. The right first molar served as a control with an injection of 0.9% NaCl solution. The topical administration of risedronate caused a significant and dose-dependent reduction of tooth movement after the orthodontic force was applied. In the second experiment, the right and left upper molars were first moved buccally for three weeks. The spring was then removed, and administration of risedronate was begun. The topical administration of risedronate inhibited relapse of the tooth in a dose-dependent manner. The administration of risedronate did not affect either overall growth of the animals or longitudinal growth of tibiae. These results suggest that topical application of risedronate may be helpful in anchoring and retaining teeth under orthodontic treatment.
Adachi
H
H
Department of Orthodontics and Pharmacology, School of Dentistry, Tohoku University, Sendai, Japan.
Igarashi
K
K
Mitani
H
H
Shinoda
H
H
D000287:Administration, Topical; D016301:Alveolar Bone Loss / Q000209:etiology / Q000517:prevention & control*; D000539:Alveolar Process / Q000187:drug effects; D000704:Analysis of Variance; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009971:Orthodontics, Corrective / Q000009:adverse effects*; D010010:Osteoclasts / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D000068296:Risedronic Acid; D014086:Tooth Mobility / Q000209:etiology / Q000517:prevention & control*; D014092:Tooth Root / Q000187:drug effects
D002121:Calcium Channel Blockers; D000068296:Risedronic Acid; D012968:Etidronic Acid